Gedea Biotech appoints Julie Waras Brogren as new CEO to lead the company into its commercialization phase
Gedea Biotech today announces a planned CEO transition. After close to ten years as CEO, Annette Säfholm has decided to step down from her role. The Board of Directors has appointed Julie Waras Brogren as the new Chief Executive Officer. Julie has more than 20 years of experience from the…
Gedea Biotech announce start of the clinical study BV2025 following CE marking of pHyph —first patients enrolled
PRESS RELEASE Lund, Sweden, January 22, 2026 Gedea Biotech today announced that the clinical trial BV2025 has started, following approval from the Swedish Medical Products Agency (Läkemedelsverket) for the treatment of bacterial vaginosis. In addition to fulfilling post-approval requirements, the…
Gedea Biotech strengthens its Board with extensive commercial expertise to support next phase
PRESS RELEASE Lund, Sweden – November 18, 2025 Gedea Biotech, an innovative Swedish life science company in women’s health, today announced the appointment of three new members to its Board of Directors: Paan Hermansson, Berit Lindholm, and Caroline Mofors. “- We are very fortunate to bring strong…
New insights into the vaginal microbiome: Emilia Lahtinen’s industrial PhD journey
At the intersection of academic research and biotech innovation, Emilia Lahtinen is pursuing her industrial PhD as a collaboration between Gedea Biotech and Karolinska Institutet (KI). Her research explores one of the
Gedea Biotech Announces CE-Marking for pHyph: A Novel Antibiotic-Free Treatment for Bacterial Vaginosis
Lund, Sweden – September 2, 2025 – Gedea Biotech, an innovative Swedish life science company, today announced that its lead product pHyph has received CE-marking under the EU Medical Device Regulation (MDR) for the treatment of bacterial vaginosis (BV). pHyph is an antibiotic-free vaginal tablet…
PRESS RELEASE Gedea Biotech Receives US Patent for Preventing Preterm Birth
Lund, Sweden, March 27, 2025 Gedea Biotech announced today that the United States Patent and Trademark Office (USPTO) has granted the company’s patent application covering the active ingredient in the company’s first product, pHyph, to prevent preterm birth (premature delivery) in pregnant women…
Gedea Biotech Reports Significant Results in Study for the Treatment of Bacterial Vaginosis
PRESS RELEASE Lund, Sweden, March 12, 2025 Gedea Biotech has completed a clinical study, the NEFERTITI-2 study, for the treatment of bacterial vaginosis, showing significantly better treatment outcomes with the company's vaginal tablet pHyph compared to the control group. This result forms the…
Gedea wins prestigious scale up award
On Thursday November 28th, at the Nordic Mentor Network For Entrepreneurship - NOME annual meeting in Copenhagen, we were honored to receive the Arvind Hundal Scale-up Award for “showing inspirational growth.” We are proud, humbled, and truly grateful for this recognition. Following in the…
Emilia, industrial doctoral student at Gedea and Karolinska Institutet
Emilia Lahtinen is n industrial Ph.D. student at Gedea and at Karolinska Institutet. Her project has the title Bacterial vaginosis: Understanding the impact of antibiotic and antibiotic-free treatments on the vaginal microbiome and risk of recurrence. Please meet her in this short interview.……